Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471330 | 0.80 | GAA (0.41) | GAAEZH2 | |
| SCHEMBL4234096 | 0.79 | HRH3 (0.59) | HRH3GPR119NAAAFPR2PROKR1 | |
| SCHEMBL1471237 | 0.78 | GAA (0.44) | GAAEZH2KCNH2 | |
| SCHEMBL1471253 | 0.78 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3GAAMMP13 | |
| SCHEMBL27622911 | 0.78 | GAA (0.41) | GAAEZH2KCNH2 | |
| SCHEMBL451934 | 0.78 | GAA (0.54) | SLC6A2SLC6A4SLC6A3GAAEZH2 | |
| Hydrochloric Acid SCHEMBL1471517 | 0.77 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3GAAMMP13 | |
| SCHEMBL20076154 | 0.76 | HRH3 (0.54) | HRH3GPR119MMP13MMP14FPR2 | |
| SCHEMBL22138868 | 0.75 | HRH3 (0.71) | HRH3GPR119SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5024491 | 0.75 | HRH3 (0.71) | HRH3GPR119SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885GPR119 31/4885NAAA 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.